Research Progress of Smeiglutide for Chronic Weight Management in Overweight Population#br#

Abstract

Abstract: Semaglutide， a kind ofglucagon-like peptide-1（GLP-1）receptor agonist，It was approved by the US Food and Drug Administration(FDA) as a hypoglycemic drug in December 2017， and officially launched in China in August 2021. Semaglutide has been used as a glucose-lowering drug since its marketing， andit was approved by the United States FDA for chronic weight management in June 2021 due to its weight-reducing effect. This article reviews the research progress of semaglutide for chronic weight management in overweight population from the aspects of mechanism of action， efficacy， safety andanalysis of costs.

Key words: font-size:medium, ">Semaglutide； Overweight population；Chronic weight management

CLC Number:

HUO Yan-Chao, JIA Qiong, WANG Zhen-zhen, GAI Ke-Ke. Research Progress of Smeiglutide for Chronic Weight Management in Overweight Population#br# [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(2): 163-166.

References

[1]Jepsen MM， Christensen MB. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity[J]. Expert Opinion on Emerging Drugs， 2021， 26(3)： 231-243.
     [2]Idrees Z， Cancarevic I， Huang L. FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade[J]. Cureus， 2022， 14(9)： e29262.
     [3]Updike WH， Pane O， Franks R， et al. Is it time to expand glucagon-like peptide-1 receptor agonist use for weight loss in patients without diabetes[J]. Drugs， 2021， 81(8)： 881-893.
     [4]Novograd J， Mullally J， Frishman WH. Semaglutide for Weight Loss： Was It Worth the Weight[J]. Cardiology in Review， 2022， 30(6)： 324-329.
     [5]Knudsen LB， Lau J. The discovery and development of liraglutide and semaglutide[J]. Frontiers in endocrinology， 2019， 10： 155.
     [6]Deacon CF， Nauck MA， Toft-Nielsen M， et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects[J]. Diabetes， 1995， 44(9)： 1126-1131.
     [7]Larsen J， Hylleberg B， Ng K， et al. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment[J]. Diabetes Care， 2001， 24(8)： 1416-1421.
     [8]Lau J， Bloch P， Schaffer L， et al. Discovery of the once-weekly glucagon-like peptide-1(GLP-1) analogue semaglutide[J]. Journal of medicinal chemistry， 2015， 58(18)： 7370-7380.
     [9]Tang-Christensen M， Larsen PJ， Goke R， et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats[J]. American Journal of Physiology-Regulatory， Integrative and Comparative Physiology， 1996， 271(4)： R848-R856.
     [10]Bloemendaal LV， IJzerman RG， Kulve JST， et al. GLP-1 receptor activation modulates appetite-and reward-related brain areas in humans[J]. Diabetes， 2014， 63(12)： 4186-4196.
     [11]Blundell J， Finlayson G， Axelsen M， et al. Effects of once‐weekly semaglutide on appetite， energy intake， control of eating， food preference and body weight in subjects with obesity[J]. Diabetes， Obesity and Metabolism， 2017， 19(9)： 1242-1251.
     [12]Ahrén B， Atkin SL， Charpentier G， et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials[J]. Diabetes， Obesity and Metabolism， 2018， 20(9)： 2210-2219.
     [13]Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus[J]. Nature Reviews Endocrinology， 2012， 8(12)： 728-742.
     [14]Baggio LL， Drucker D J. Glucagon-like peptide-1 receptors in the brain： controlling food intake and body weight[J]. The Journal of clinical investigation， 2014， 124(10)： 4223-4226.
     [15]Wilding JPH， Batterham RL， Calanna S， et al. Once-weekly semaglutide in adults with overweight or obesity[J]. New England Journal of Medicine， 2021， 385(1)： e4.
     [16]Davies M， Frch L， Jeppesen OK， et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity， and type 2 diabetes(STEP 2)： a randomised， double-blind， double-dummy， placebo-controlled， phase 3 trial[J]. The Lancet， 2021， 397(10278)： 971-984.
     [17]Wing RR， Lang W， Wadden TA， et al. Look AHEAD Research Group Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes[J]. Diabetes Care， 2011， 34(7)： 1481-1486.
     [18]Wadden TA， Bailey TS， Billings LK， et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity： the STEP 3 randomized clinical trial[J]. Jama， 2021， 325(14)： 1403-1413.
     [19]Rubino D， Abrahamsson N， Davies M， et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity： the STEP 4 randomized clinical trial[J]. Jama， 2021， 325(14)： 1414-1425.
     [20]何晓东，李琴，刘慧敏，等.司美格鲁肽周制剂治疗成人超重和肥胖有效性与安全性的系统评价和Meta分析[J]. 中国医院药学杂志，2022，42(16)：1709-1715.
     [21]He L， Wang J， Ping F， et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases： a systematic review and meta-analysis of randomized clinical trials[J]. JAMA Internal Medicine， 2022， 182(5)： 513-519.
     [22]Arastu N， Cummins O， Uribe W， et al. Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese， non-diabetic adults： a systematic review & meta-analysis[J]. International Journal of Clinical Pharmacy， 2022： 1-8.
     [23]Schutz DD， Busetto L， Dicker D， et al. European practical and patient-centred guidelines for adult obesity management in primary care[J]. Obesity facts， 2019， 12(1)： 40-66.
     [24]Patoulias D， Papadopoulos C， Kassimis G， et al. Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity[J]. American Journal of Cardiology， 2022， 175： 182-184.

Research Progress of Smeiglutide for Chronic Weight Management in Overweight Population#br#

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	DAI Qi, LI Kang-xi, YE Qiao-bo, WEN Yong-sheng, XU Li, LI Ji. Reaserch Progress on Chemical Constituents，Pharmacological Effects and Toxicology of Bombyx Batryticatus [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 402-408.
[2]	ZHAO Lei, YANG Ming, WANG Hao, MA yu, MA Jin-gan, JIANG Da-cheng, WANG Lu-hong, ZAN Ke. Investigation and Risk Assessment of Mycotoxins in Seabuckthorn during Different Harvesting Periods and Drying Processes [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 377-383.
[3]	HONG Shu-hua, LIN Qi-shan, CHAI Jiang-hong, PAN Hong-ju. Study on the Determination of Zopiclone Related Substances and the Influence of Correction Factor [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 384-388.
[4]	LI Yue-chen, CUI Shao-jing, ZHAO Yue-ran. Determination of Aflatoxins in Huoxuezhitong Capsules by High Performance Liquid Chromatography Coupled with Post-column Photochemical Derivatization [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 390-395.
[5]	TIAN Jie, HAO Ai-yu, LU Lin, ZOU Pian, DONG Bin. Effect of Several Drug Compatibility on Sub-visible Particles in Infusions with Common Plastic Packagings [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 396-401.
[6]	YANG Yan-qing, CHEN Chun-mei, CHEN Wei, Wu Rui, WANG Xue-chang, DUAN Lian. Rapid Health Technology Evaluation of Sintilimab as First-line Treatment for Advanced Non-small Cell Lung Cancer [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 409-415.
[7]	JIANG Yi-Fan, CHEN Li-ping, ZHANG Ruo-yu, WU Pei-hao, QIU Jia-min, XUAN Jian-wei, BI Hui-chang. Construction of Clinical Comprehensive Value Evaluation System for Acid-inhibiting Drugs [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 416-421.
[8]	HUA Min-fan, SONG Cang-sang, LI Xing-de, LU Wei, MAO Pan-pan, WANG Guo-hui. Medication Adherence Forecast Model Research Progress in Clinical Application [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 422-425.
[9]	HUANG Bo, CAO Xiao-ming. Safety Analysis of Isotonic and Hypotonic Contrast Media for Coronary Angiography in Elderly Patients with Renal Impairment [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 426-429.
[10]	ZHANG Wen, YANG Wei-bing. Effects of Vitamin D Combined with Etocoxib on Rehabilitation，Bone Metabolism and Inflammation in Elderly Patients after Knee Replacement [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 430-434.
[11]	TIAN Jin-ya, DUAN Xiao-kai, FAN Shi-zhen. Effects of Budesonide combined with Ipratropium Bromide Solution on Lung Function， Blood Gas Analysis and Th1/Th2 Cytokines with Chronic Bronchitis [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 435-438.
[12]	ZHANG He-feng, LIANG Yu, LIU Ying, ZOU Ling-long, . Introduction of Bioanalytical Strategies and Methodologies for Genetically Modified Cell Therapy Products [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 369-376.
[13]	ZHANG He-feng, LIANG Yu, LIU Ying, ZOU Ling-long, . Bioanalysis of Gene Therapy Products： Method Development Strategy [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 361-368.
[14]	ZHANG Yu, LI Yu-man, XIA Xu-dong. Analysis of Suspected ADR Monitoring Data of Ginkgo Injection Preparations [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 439-444.
[15]	YAO Qing, LIU Ying, WANG Xiao-fang, GAO Ning, WANG Miao. Excel Calculates the Population Bioequivalence of Special Preparations [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(4): 332-337.